Global Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market Report 2018

News provided by

Sep 18, 2018, 08:45 ET

DUBLIN, Sept. 18, 2018 /PRNewswire/ --

The "Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

The "Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025" report provides an extensive study on the marketed, clinical and preclinical products / product candidates for management of chronic pain. The report also features a detailed overview of the devices that are used for the treatment / management of pain associated with chronic clinical conditions.

Owing to the rapid onset of their medicinal effect, which offers immediate relief with high efficacy, opioids are still considered to be one of the most widely used pharmacological interventions for the management of moderate to severe forms of pain. However, these drugs are known to induce a euphoric state upon intake, often causing patients to abuse them; increased recreational use of opioids has also been shown to lead to drug addiction.

The over-prescription of such medicinal products, which promotes their misuse, is considered as one of the root causes of the opioid crisis. In a recent article, published in 2017, 11.5 million individuals were reported to have been caught misusing prescription opioids, while over 42,000 died from opioid overdose, in the US alone. Moreover, opioid abuse was estimated to have been responsible for over USD 500 billion worth of economic deficit (in the US) due to loss of productivity and healthcare costs.

The opioid crisis has prompted drug manufacturers to develop non-addictive, non-narcotic-based therapeutics / analgesics for the management of pain. Unlike opioids, non-opioid drugs do not affect receptors present in the brain and, thus, are not addictive. These drugs work directly on injured / diseased body tissues and generally block the production of prostaglandins by inhibiting the cyclooxygenase (COX) enzyme at the site of injury / infection, thereby, decreasing the generation of pain mediators within the peripheral nervous system.

Additionally, there are various pain management devices that have been reported to significantly reduce or eliminate the need for pharmacological interventions. Such devices are increasingly being used to treat a variety of clinical conditions that are characterized by chronic pain and offer the convenience of being used in the homecare setting as well. However, it is imperative for patients to consult qualified healthcare professionals, who have the required understanding of such therapeutic options, prior to using such devices

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term, for the period 2018-2025. The report includes a detailed market segmentation on the basisof indication (chronic back pain, lumbar radiculopathy, migraine, osteoarthritis and neuropathic pain), type of molecule (small molecule and biologic), mechanism of action (CGRP inhibitors, COX/ NGF inhibitors, TRPV1 receptor antagonists, channel blockers and others) and geography (North America, Europe, Asia Pacific and rest of the World). In addition, the report features an opportunity analysis for the chronic pain management devices market.

The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Ryan Jeffcoat (Director of Clinical Affairs & New Markets, AVACEN Medical), Lisa Robin (Chief Advocacy Officer, Federation of State Medical Boards), Nelson Hendler (Chief Executive Officer, Mensana Clinic Diagnostics) and Mark Wiederhold (Chief Executive Officer, Virtual Reality Medical Center). All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Definition of Pain
3.2. Classification of Pain
3.2.1. Acute Pain
3.2.2. Chronic Pain
3.2.2.1. Classification of Chronic Pain
3.2.2.2. Chronic Pain and Mental Health
3.3. Pain Management
3.3.1. Therapeutics for Pain Management
3.3.2. Devices for Pain Management
3.3.3. Other Therapeutic Modalities and Interventions for Pain Management
3.4. Future Prospects

4. CHRONIC PAIN MANAGEMENT: UNMET NEED ANALYSIS
4.1. Chapter Overview
4.2. Unmet Need Analysis
4.2.1. Introduction
4.2.2. Patient Blogs
4.2.3. Published Literature
4.2.4. Social Media Platforms
4.2.5. Expert Opinions
4.2.5.1. Jeffrey Curtis, MD, University of Alabama
4.2.5.2. Stephan Silberstein, MD, Jefferson University Hospital
4.2.5.3. Jeffrey Gudin, MD, Englewood Hospital and Medical Center
4.2.5.4. Kevin Zacharoff, MD, SUNY Stonybrook School of Medicine
4.2.5.5. Philip J Mease, MD, University of Washington School of Medicine
4.2.5.6. John D Reveille, MD, McGovern Medical School
4.2.5.7. Christopher R McCurdy, PhD, University of Florida
4.2.6. Concluding Remarks: Key Unmet Needs in Chronic Pain Management

5. PIPELINE REVIEW: MARKETED AND DEVELOPMENT DRUGS
5.1. Chapter Overview
5.2. Non-Opioid Drugs for Chronic Pain Management: Marketed and Development Pipeline
5.3. Non-Opioid Drugs for Chronic Pain Management: Pipeline Analysis
5.3.1. Analysis by Phase of Development
5.3.2. Analysis by Type of Molecule
5.3.3. Analysis by Mechanism of Action
5.3.4. Analysis by Route of Administration
5.3.5. Analysis by Target Therapeutic Indication(s)
5.3.6. Analysis by Size of Employee Base of Developer
5.3.7. Pipeline Analysis: Leading Players
5.3.8. Developer Logo Landscape: Distribution by Size and Location
5.3.9. Mirror Analysis: Distribution by Type of Indication, Number of Molecules and Manufacturer
5.3.10. Heptagon Representation: Distribution by Target Disease Indication and Phase of Development
5.3.11. Funnel Analysis: Distribution by Target Disease Indications, Route of Administration and Phase of Development

6. LIFECYCLE MANAGEMENT STRATEGIES FOR MARKETED PRODUCTS
6.1. Introduction
6.2. Product Profile: Duexis (Horizon Pharma)
6.2.1. Overview
6.2.2. Mechanism of Action
6.2.3. Life Cycle Management Strategies
6.2.4. Partnerships and Collaborations
6.3. Product Profile: Gralise (Depomed)
6.3.1. Overview
6.3.2. Mechanism of Action
6.3.3. Life Cycle Management Strategies
6.3.4. Legal Defense
6.3.5. Partnerships and Collaborations
6.3.5.1. Actavis
6.3.5.2. Abbott
6.4. Product Profile: Horizant (Arbor Pharmaceuticals)
6.4.1. Overview
6.4.2. Mechanism of Action
6.4.3. Life Cycle Management Strategies
6.4.3.1. Extension of Patent Exclusivity
6.4.3.2. Indication Expansion
6.4.4. New Dose Strength
6.4.5. Partnerships and Collaborations
6.4.5.1. GlaxoSmithKline
6.4.5.2. Arbor Pharmaceutical
6.5. Product Profile: Vimovo (AstraZeneca and Pozen)
6.5.1. Overview
6.5.2. Mechanism of Action
6.5.3. Life Cycle Management Strategies
6.5.3.1. Pricing
6.5.3.2. Geographical Expansion
6.5.4. Legal Defense
6.5.5. Partnerships and Collaborations
6.5.5.1. AstraZeneca
6.5.5.2. Horizon Pharma

7. DRUG PROFILES: LATE STAGE MOLECULES
7.1. Chapter Overview
7.2. Drug Profile: Aimovig / Erenumab
7.3. Drug Profile: Analgecine
7.4. Drug Profile: Atogepant / AGN 241689 / MK 8031
7.5. Drug Profile: Civamide / Civanex / Zucapsaicin
7.6. Drug Profile: CNTX-4975
7.7. Drug Profile: Eptinezumab / ALD403
7.8. Drug Profile: Fasinumab
7.9. Drug Profile: Fremanezumab
7.10. Drug Profile: Galcanezumab / LY2951742
7.11. Drug Profile: Lasmiditan / COL-144
7.12. Drug Profile: Mirogabalin / DS-5565
7.13. Drug Profile: MPC-06-ID
7.14. Drug Profile: Neridronate
7.15. Drug Profile: NTM-001
7.16. Drug Profile: NTM-002
7.17. Drug Profile: Perampanel (E2007)
7.18. Drug Profile: POSIMIR (SABER-Bupivacaine)
7.19. Drug Profile: Ralfinamide
7.20. Drug Profile: SP-102
7.21. Drug Profile: T-121
7.22. Drug Profile: Tanezumab
7.23. Drug Profile: Tetrodotoxin / TTX
7.24. Drug Profile: Ubrogepant / MK-1602
7.25. Drug Profile: YHD1119 / PREGABALIN

8. CHRONIC PAIN MANAGEMENT DEVICES: MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Devices for Pain Management: Database
8.3. Devices for Pain Management: Database Analysis
8.3.1. Analysis by Type of Devices
8.3.2. Analysis by Mechanism of Action
8.3.3. Analysis by Modality of Device
8.3.4. Analysis by Site of Application on Body
8.3.5. Analysis by Convenience of Use
8.3.6. Analysis by Location of Developer(s)
8.3.7. Analysis by Company Size

9. DEVICE COMPETITIVENESS ANALYSIS AND PROFILES
9.1. Chapter Overview
9.2. Methodology
9.3. Implants
9.3.1. Assumptions, Limitations and Key Evaluable Parameters
9.3.2. Device Competitive Analysis for Implants: Results
9.3.3. Device Profiles
9.3.3.1. Freedom SCS System (Stimwave)
9.3.3.2. VIVENDI (BlueWind Medical)
9.4. Wearables
9.4.1. Assumptions, Limitations and Parameters Evaluated
9.4.2. Device Competitive Analysis for Wearables: Results
9.4.3. Device Profiles
9.4.3.1. Avail Wireless (Omron Healthcare)
9.4.3.2. Cefaly (Cefaly Technologies)
9.4.3.3. Electro-Mesh Garments (Prizm Medical)
9.4.3.4. Micro-Z (Prizm Medical)
9.4.3.5. PainPod MI (PainPod)
9.4.3.6. PainPod XPV (PainPod)
9.4.3.7. Quell Relief (Neurometrix)
9.4.3.8. SENSUS Pain Management System (Neurometrix)
9.4.3.9. Smart Relief Back (Chattem)
9.5. Other Devices
9.5.1. Assumptions, Limitations and Parameters Evaluated
9.5.2. Devices Competitive Analysis for Other Devices: Results
9.5.3. Device Profiles
9.5.3.1. Silk'n Relief (Silk'n Therapy)
9.5.3.2. The Wellness Pro Plus (ElectroMedical Technologies)

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Non-Opioid Drugs and Devices for Chronic Pain Management: Recent Partnerships and Collaborations
10.3.1. Analysis by Year of Agreement
10.3.2. Analysis by Quarterly Trends
10.3.3. Analysis by Type of Partnership
10.3.4. Analysis by Most Active Players
10.3.5. Analysis by Geographical Activity

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Non-Opioid Drugs for Chronic Pain Management: Funding and Investment Analysis
11.3.1. Analysis by Cumulative Number of Funding Instances
11.3.2. Analysis by Cumulative Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Most Active Players
11.3.5. Analysis by Most Active Investors
11.4. Concluding Remarks

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions
12.3. Forecast Methodology
12.4. Overall Non-Opioids Drugs for Chronic Pain Management Market, 2018-2025
12.4.1. Non-Opioid Drugs Market: Distribution by Therapeutic Area
12.4.2. Non-Opioid Drugs Market: Distribution by Molecule Type
12.4.3. Non-Opioid Drugs Market: Distribution by Mechanism of Action
12.4.4. Non-Opioid Drugs Market: Distribution by Geography
12.5. Non-Opioid Drugs Market: Product-Wise Sales Forecasts
12.5.1. Qutenza (Accorda Therapeutics)
12.5.2. Vimovo (Horizon Pharma)
12.5.3. Duexis (Horizon Pharma)
12.5.4. Gralise (Depomed)
12.5.5. Horizant (Arbor Pharmaceuticals)
12.5.6. Zilretta (Flexion Therapeutics)
12.5.7. Ztlido (Sorrento Therapeutics)
12.5.8. Aimovig (Amgen)
12.5.9. Fremanezumab (Teva Pharmaceuticals)
12.5.10. Galcanezumab (Eli Lilly)
12.5.11. Mirogabalin (DS-5565) (Daiichi Sankyo)
12.5.12. YHD1119 (Yuhan corporation)
12.5.13. GLA5PR (GL PharmTech)
12.5.14. Eptinezumab (Alder Biopharmaceuticals)
12.5.15. ALLOD-2 (Allodynic Therapeutics)
12.5.16. PainBrake (GT Biopharma)
12.5.17. Neridronate (Grunenthal)
12.5.18. Fasinumab (Regeneron Pharmaceuticals)
12.5.19. SP-102 (Semnur Pharmaceuticals)
12.5.20. CNTX-4975 (Centrexion Therapeutics)
12.5.21. MPC-06-ID (Mesoblast)
12.5.22. Tanezumab
12.6. Overall Pain Management Devices Market, 2018-2025
12.6.1. Pain Management Devices Market: Distribution by Geography
12.6.2. Pain Management Devices Market: Distribution by Type of Device
12.6.3. Pain Management Devices Market: Distribution by Mechanism of Action

13. CONCLUSION
13.1. The Opioid Crisis is Responsible for a Number of Fatalities Due to the Abuse of Controlled Substances; Drug Developers are Actively Attempting to Develop Alternative Pain Management Solutions
13.2. The Non-Opioid Therapeutics Market is Characterized by a Robust Pipeline of Candidate Drugs Being Developed for a Variety of Chronic Clinical Conditions
13.3. A Variety of Innovative Devices are also Available for the Management of Various Clinical Conditions Characterized by Chronic Pain
13.4. Increasing Partnership Activity and Financial Support from Various Investors are Indicative of Lucrative Future Potential
13.5. Given the Existing Unmet Needs, the Market is Anticipated to Grow at a Steady Pace in the Foreseen Future

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Mark Wiederhold, Chief Executive Officer, Virtual Reality Medical Center (Q2 2018)
14.3. Lisa Robin, Chief Advocacy Officer, Federation of State Medical Boards (Q2 2018)
14.4. Nelson Hendler, Chief Executive Officer, Mensana Clinic Diagnostics (Q2 2018)
14.5. Ryan Jeffcoat, Director of Clinical Affairs and New Markets, AVACEN Medical (Q1 2018)

For more information about this report visit https://www.researchandmarkets.com/research/lctv29/global_nonopioid?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets